ReviewBMC women's health2025
MRI and FDG PET/CT findings for small cell neuroendocrine carcinoma of the ovary: a case report and literature review.
Review in BMC women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CT imaging characteristics of ovarian small cell carcinoma: correlation with clinicopathology and prognosis.BMC medical imaging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOvarian small cell neuroendocrine carcinoma (OSCNEC) is rare and few cases have been reported, which makes preoperative diagnosis difficult. Moreover, no reports have yet described detailed imaging findings or findings of positron emission tomography with fluorine-18 fluorodeoxyglucose ( CASE PRESENTATION: A 74-year-old woman with clinical symptoms of abdominal distension was referred to our hospital because of a pelvic mass detected by ultrasonography at another hospital. Serum levels of cancer antigen 125 and neuron-specific enolase (NSE) were both elevated, at 203.0 U/mL (normal range 0-35.0 U/ml) and 47.6 ng/ml (normal range 0-16.3 ng/ml), respectively. Magnetic resonance imaging at 3.0 Tesla showed a multilocular cystic tumor 18 cm in diameter in the pelvic cavity. The tumor had irregular septa and included a solid component. The cystic component showed partially high intensity suggesting hemorrhage on fat-suppressed T1WI. The solid component showed high intensity on diffusion-weighted imaging and contrast enhancement on contrast-enhanced fat-suppressed T1WI. Irregular peritoneal thickening and nodules suggesting peritoneal dissemination were also detected.
conclusionsOSCNEC could be considered when elevated serum NSE at diagnosis and hematogenic spread such as bone or liver metastases are found in a patient with a primary malignant ovarian tumor without a lung tumor on imaging, although MR findings of OSCNEC were not specific enough to differentiate it from other ovarian cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.